Skip to content
value.today
UroGen Pharma Ltd. logo

UroGen Pharma Ltd.

URGN
$1.8 Bmarket cap on Oct 15, 2026+312.5% since Jan 2024
1D
-4.4%
Compare
World rank
#6,792
Revenue
$110 M
For year ending December-2025
Net income
$-153 M
-139.8% margin
SEC filing
Employees
—

UroGen Pharma Ltd. in brief

UroGen Pharma Ltd. is a listed company in the Biotechnology industry, based in New York, USA. It was founded in 2004. Its market value was $1.8 B on 15 October 2026, which makes it the 6,792nd largest listed company in the world and the 1,711th largest in the USA on this site. In the year to December 2025 it had sales of $110 M and a net loss of $153 M. Elizabeth A. Barrett is its chief executive. Its largest product and service lines by sales in 2025 were Jelmyto (86%) and Zusduri (14%). Its shares trade under the symbol URGN (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About UroGen Pharma Ltd.

UroGen Pharma is a Biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. The company annual revenue is 3.5 million USD and 156 employees as on 2020. The headquarters is in USA.

UroGen Pharma Ltd. timeline

4 events, 2004–2025
  1. 2004
  2. 🏁
    · approximate
    Founded
  3. 2016
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2017
  6. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 5 May 2017; shares registered for exchange trading on 1 May 2017.
  7. 2025
  8. 💰
    Record revenue of $110 million
    FY2025, the highest of the 8 years on record.

Events of UroGen Pharma Ltd. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$636 M$1.3 B$1.9 B$2.5 B2020202120222023202420252026

World rank over time

▲ up 2,445 places since 2020
2020-01-01: #9255#9,25520202021-01-01: #12313#12,31320212022-01-07: #18931#18,93120222022-12-25: #18356#18,35620222023-07-30: #12377#12,37720232024-01-05: #13466#13,46620242026-03-08: #4725#4,72520262026-08-01: #5776#5,77620262026-10-14: #6621#6,62120262026-10-15: #6810#6,8102026

Rank in USA: #2,218 (Jan 2020) · #2,942 (Jan 2021) · #3,852 (Jan 2022) · #3,739 (Dec 2022) · #2,637 (Jul 2023) · #2,655 (Jan 2024) · #865 (Mar 2026) · #1,557 (Aug 2026) · #1,665 (Oct 2026) · #1,712 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
16.3×
Price / book
—
Free cash flow yield
-9.1%
Net margin
-139.8%
Operating margin
-113.7%
Return on equity
—
Liabilities / assets
152.6%
Net debt
$14M
Revenue growth
+21.4%
R&D / revenue
61.1%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $1M, net income $-76M$1MFY18Fiscal year ending Dec 2019: revenue $0M, net income $-105M$0MFY19Fiscal year ending Dec 2020: revenue $12M, net income $-128M$12MFY20Fiscal year ending Dec 2021: revenue $48M, net income $-111M$48MFY21Fiscal year ending Dec 2022: revenue $64M, net income $-110M$64MFY22Fiscal year ending Dec 2023: revenue $83M, net income $-102M$83MFY23Fiscal year ending Dec 2024: revenue $90M, net income $-127M$90MFY24Fiscal year ending Dec 2025: revenue $110M, net income $-153M$110MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$110M+21.4%$-125M$-153M-139.8%
Dec 2024$90M+9.3%$-97M$-127M-140.3%
Dec 2023$83M+28.5%$-66M$-102M-123.6%
Dec 2022$64M+34.0%$-79M$-110M-170.6%
Dec 2021$48M+307.1%$-92M$-111M-230.7%
Dec 2020$12M+58900.0%$-127M$-128M-1088.8%
Dec 2019$0M-98.2%$-109M$-105M-525750.0%
Dec 2018$1M—$-77M$-76M-6695.6%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-162M$0M$-163M——
Dec 2024$-97M$0M$-97M——
Dec 2023$-76M$0M$-77M——
Dec 2022$-88M$0M$-88M——
Dec 2021$-85M$1M$-86M$-4.96—
Dec 2020$-106M$1M$-107M$-5.90—
Dec 2019$-71M$0M$-71M$-5.12—
Dec 2018$-37M$1M$-38M$-4.80—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024: revenue $25M, net income $-38M$25MDec ’24Three months to Mar 2025: revenue $20M, net income $-44M$20MMar ’25Three months to Jun 2025: revenue $24M, net income $-50M$24MJun ’25Three months to Sep 2025: revenue $27M, net income $-33M$27MSep ’25Three months to Dec 2025 (from the annual report): revenue $38M, net income $-26M$38MDec ’25Three months to Mar 2026: revenue $51M, net income $-24M$51MMar ’26Three months to Jun 2026: revenue $72M, net income $-14M$72MJun ’26Three months to Sep 2026: revenue $89M, net income $-1M$89MSep ’26

Latest quarter to Sep 2026: revenue $89M (+223.9% on a year earlier), net income $-1M. Lighter bars: fourth quarters worked out from the annual report.

SEC filings

Official filings of UroGen Pharma Ltd. with the US Securities and Exchange Commission.

Annual results

Revenue
$110 M
Operating income
$-125 M
Net income
$-153 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$200 M
Total liabilities
$306 M
Total equity
$-105 M

As of December-2025

Top 100 institutional investors in UroGen Pharma Ltd.#

As of Sep 30, 2026
221 institutions held 40.6 M shares (about 82.8% of the shares outstanding) on Sep 30, 2026. The ten largest hold 43.5%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in UroGen Pharma Ltd.
#InstitutionShares heldChange (shares)% heldValueFiled
1RTW Investments, LP4,543,8950 (0.00%)9.26%$185 MNov 16, 2026
2BlackRock, Inc.3,108,202-93,259 (-2.91%)6.34%$126 MNov 13, 2026
3Kynam Capital Management, LP2,434,2070 (0.00%)4.96%$99 MNov 16, 2026
4Jefferies Financial Group Inc.2,199,6520 (0.00%)4.48%$89 MNov 5, 2026
5Morgan Stanley2,174,808-401,555 (-15.59%)4.43%$88 MNov 13, 2026
6Acorn Capital Advisors, LLC1,648,420-25,000 (-1.49%)3.36%$67 MNov 16, 2026
7Opaleye Management Inc.1,439,9960 (0.00%)2.94%$59 MNov 16, 2026
8American Century Companies Inc1,375,304-310,415 (-18.41%)2.80%$56 MNov 12, 2026
9D. E. Shaw & Co., Inc.1,283,889+138,070 (+12.05%)2.62%$52 MNov 16, 2026
10Silverarc Capital Management, LLC1,148,689-153,290 (-11.77%)2.34%$47 MNov 12, 2026
11Orbimed Advisors LLC988,487+312,300 (+46.19%)2.02%$40 MNov 16, 2026
12State Street Corp975,787-27,284 (-2.72%)1.99%$40 MNov 12, 2026
13Frontier Capital Management Co LLC936,144-572,403 (-37.94%)1.91%$38 MNov 16, 2026
14MPM Bioimpact LLC909,691-23,724 (-2.54%)1.85%$37 MNov 16, 2026
15Goldman Sachs Group Inc848,342+28,508 (+3.48%)1.73%$34 MNov 16, 2026
16Migdal Insurance & Financial Holdings Ltd.770,9090 (0.00%)1.57%$31 MNov 9, 2026
17Parkman Healthcare Partners LLC750,202+576,138 (+330.99%)1.53%$30 MNov 16, 2026
18Geode Capital Management, LLC617,513+7,149 (+1.17%)1.26%$25 MNov 6, 2026
19Woodline Partners LP500,7260 (0.00%)1.02%$20 MNov 16, 2026
20Boxer Capital Management, LLC500,0000 (0.00%)1.02%$20 MNov 16, 2026
21Elmind Capital, LP491,100+371,100 (+309.25%)1.00%$20 MNov 16, 2026
22Vanguard Portfolio Management LLC462,075+5,517 (+1.21%)0.94%$19 MNov 13, 2026
23Two Sigma Investments, LP406,299+257,336 (+172.75%)0.83%$17 MNov 16, 2026
24ADAR1 Capital Management, LLC369,785+117,390 (+46.51%)0.75%$15 MNov 16, 2026
25Nomura Asset Management International Inc.366,973New0.75%$15 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in UroGen Pharma Ltd.
#InstitutionShares heldChange (shares)% heldValueFiled
26Walleye Capital LLC348,116New0.71%$14 MNov 13, 2026
27Hennion & Walsh Asset Management, Inc.309,584+32,888 (+11.89%)0.63%$13 MOct 13, 2026
28Federated Hermes, Inc.305,217+304,259 (+31759.81%)0.62%$12 MNov 12, 2026
29Northern Trust Corp303,188-1,382 (-0.45%)0.62%$12 MNov 16, 2026
30Next Century Growth Investors LLC297,083New0.61%$12 MNov 13, 2026
31Schonfeld Strategic Advisors LLC295,809+263,350 (+811.33%)0.60%$12 MNov 16, 2026
32Oberweis Asset Management Inc/295,625New0.60%$12 MNov 16, 2026
33Qube Research & Technologies Ltd287,222New0.59%$12 MNov 13, 2026
34AQR Capital Management LLC283,615+134,387 (+90.05%)0.58%$12 MNov 16, 2026
35Millennium Management LLC268,902+162,210 (+152.04%)0.55%$11 MNov 16, 2026
36UBS Group AG266,218+144,757 (+119.18%)0.54%$11 MNov 10, 2026
37Nuveen, LLC240,822+148,720 (+161.47%)0.49%$10 MNov 10, 2026
38Bank Of America Corp /de/235,848-239,854 (-50.42%)0.48%$10 MNov 16, 2026
39FMR LLC230,871+33,773 (+17.14%)0.47%$9 MNov 10, 2026
40Soleus Capital Management, L.P.230,274-599,536 (-72.25%)0.47%$9 MNov 16, 2026
41Rice Hall James & Associates, LLC226,046-74,604 (-24.81%)0.46%$9 MNov 16, 2026
42Jpmorgan Chase & Co210,356+170,812 (+431.95%)0.43%$9 MNov 12, 2026
43Superstring Capital Management LP184,392-6,921 (-3.62%)0.38%$7 MNov 16, 2026
44Russell Investments Group, Ltd.183,076+88,097 (+92.75%)0.37%$7 MNov 6, 2026
45ING Groep NV180,000New0.37%$7 MNov 10, 2026
46Wellington Management Group LLP168,792+53,430 (+46.32%)0.34%$7 MNov 16, 2026
47J. Goldman & Co LP149,139-63,636 (-29.91%)0.30%$6 MNov 16, 2026
48Charles Schwab Investment Management Inc128,297-73 (-0.06%)0.26%$5 MNov 16, 2026
49Squarepoint Ops LLC117,199+105,500 (+901.79%)0.24%$5 MNov 9, 2026
50Tidal Investments LLC112,990+11,153 (+10.95%)0.23%$5 MNov 13, 2026
51Neo Ivy Capital Management111,430New0.23%$5 MNov 13, 2026
52Aisling Capital Management LP108,0000 (0.00%)0.22%$4 MNov 12, 2026
53Privium Fund Management B.V.107,915-102,085 (-48.61%)0.22%$4 MNov 3, 2026
54Susquehanna International Group, LLP106,837+100,055 (+1475.30%)0.22%$4 MNov 16, 2026
55Informed Momentum Co LLC106,013+26,742 (+33.73%)0.22%$4 MNov 16, 2026
56Atom Investors LP104,599+57,935 (+124.15%)0.21%$4 MNov 16, 2026
57Bank of New York Mellon Corp102,516-10,512 (-9.30%)0.21%$4 MNov 5, 2026
58Arrowstreet Capital, Limited Partnership89,885New0.18%$4 MNov 13, 2026
59Swiss National Bank78,800+1,000 (+1.29%)0.16%$3 MNov 12, 2026
60BNP Paribas Financial Markets77,648+34,049 (+78.10%)0.16%$3 MNov 12, 2026
61Oak Ridge Investments LLC74,743-13,848 (-15.63%)0.15%$3 MOct 30, 2026
62State Of Wisconsin Investment Board74,403+39,349 (+112.25%)0.15%$3 MNov 16, 2026
63XTX Topco Ltd72,388+53,002 (+273.40%)0.15%$3 MNov 16, 2026
64Truist Financial Corp72,303+17 (+0.02%)0.15%$3 MOct 30, 2026
65Panagora Asset Management Inc67,456-6,568 (-8.87%)0.14%$3 MNov 12, 2026
66Jump Financial, LLC65,100New0.13%$3 MNov 13, 2026
67Raymond James Financial Inc60,148New0.12%$2 MNov 12, 2026
68Jacobs Levy Equity Management, Inc55,667+34,971 (+168.97%)0.11%$2 MNov 16, 2026
69ARK Investment Management LLC54,250-47,258 (-46.56%)0.11%$2 MNov 13, 2026
70Rhumbline Advisers53,588-1,334 (-2.43%)0.11%$2 MNov 10, 2026
71Wells Fargo & Company/mn49,901-30,333 (-37.81%)0.10%$2 MNov 16, 2026
72Deutsche Bank AG\47,292-4,258 (-8.26%)0.10%$2 MNov 6, 2026
73Polen Capital Management LLC46,801+17,186 (+58.03%)0.10%$2 MNov 13, 2026
74Voya Investment Management LLC46,629-24,631 (-34.56%)0.10%$2 MNov 10, 2026
75California State Teachers Retirement System44,9490 (0.00%)0.09%$2 MNov 13, 2026
76ExodusPoint Capital Management, LP44,645New0.09%$2 MNov 16, 2026
77Alliancebernstein L.P.43,7100 (0.00%)0.09%$2 MNov 16, 2026
78UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC42,767+41,893 (+4793.25%)0.09%$2 MNov 16, 2026
79Royal Bank Of Canada38,930+27,870 (+251.99%)0.08%$2 MNov 16, 2026
80Coastal Bridge Advisors, LLC38,250+1,250 (+3.38%)0.08%$2 MNov 18, 2026
81Cetera Investment Advisers37,422+8,470 (+29.26%)0.08%$2 MNov 13, 2026
82Vanguard Fiduciary Trust Co36,275-932 (-2.50%)0.07%$1 MNov 13, 2026
83Legal & General Group Plc35,8300 (0.00%)0.07%$1 MNov 16, 2026
84Citadel Advisors LLC35,665+22,680 (+174.66%)0.07%$1 MNov 16, 2026
85Price T Rowe Associates Inc /MD/35,343+340 (+0.97%)0.07%$1 MNov 16, 2026
86Prudential Financial Inc34,738+27,763 (+398.04%)0.07%$1 MNov 16, 2026
87Bender Robert & Associates34,701New0.07%$1 MOct 21, 2026
88Focus Partners Wealth33,434+373 (+1.13%)0.07%$1 MNov 12, 2026
89Engineers Gate Manager LP33,278+16,900 (+103.19%)0.07%$1 MNov 16, 2026
90Barclays PLC31,294+21,119 (+207.56%)0.06%$1 MNov 6, 2026
91Algert Global LLC31,120-1,230 (-3.80%)0.06%$1 MNov 17, 2026
92Gilder Gagnon Howe & Co LLC30,148New0.06%$1 MNov 16, 2026
93VANGUARD ASSET MANAGEMENT, Ltd29,666+3,662 (+14.08%)0.06%$1 MNov 13, 2026
94Ameriprise Financial Inc29,181-2,487 (-7.85%)0.06%$1 MNov 16, 2026
95Jain Global LLC26,014+19,112 (+276.91%)0.05%$1 MNov 16, 2026
96Invesco Ltd.24,868-1,059 (-4.08%)0.05%$1 MNov 12, 2026
97MetLife Investment Management, LLC24,8650 (0.00%)0.05%$1 MNov 16, 2026
98Palo Alto Investors LP24,5000 (0.00%)0.05%$1 MNov 16, 2026
99Franklin Templeton Inc21,836+2,573 (+13.36%)0.04%$1 MNov 12, 2026
100MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.20,347+811 (+4.15%)0.04%$1 MNov 16, 2026

All 221 institutional investors, with who bought and sold →

Superinvestors holding UroGen Pharma Ltd.

1 of the well-known investors value.today follows, from their newest Form 13F.

Mutual funds holding UroGen Pharma Ltd.#

107 funds hold shares worth $211 M (about 12.0% of the company). Since their previous reports 68 added shares and 24 sold, buying $26 M net.
Mutual funds holding UroGen Pharma Ltd.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors1.11 M$41 M2.3%0.05%+13%Jun 30, 2026
🇺🇸 Small Cap Growth FundAmerican Century Investment Management, Inc.874,981$33 M1.8%0.60%no changeJul 31, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC465,265$18 M0.95%0.05%+17%Jul 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors339,426$12 M0.69%0.08%+26%Jun 30, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors290,394$11 M0.59%0.12%+1.5%Jun 30, 2026
🇺🇸 State Street SPDR Portfolio Developed World ex-US ETFSSGA Funds Management, Inc.184,678$7 M0.38%0.02%−0.1%Jun 30, 2026
🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC175,588$6 M0.36%0.11%+42%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.206,762$6 M0.42%0.03%+13%May 31, 2026
🇺🇸 Vanguard Explorer Value FundFrontier Capital Management Company, LLC189,986$5 M0.39%0.43%+52%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors143,206$5 M0.29%0.35%+41%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.103,478$4 M0.21%0.05%+17%Jul 31, 2026
🇺🇸 Calamos Timpani Small Cap Growth FundCalamos Advisors LLC97,953$4 M0.20%0.49%newJul 31, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.118,284$3 M0.24%0.02%+0.1%May 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC79,645$3 M0.16%0.05%+28%Jun 30, 2026
🇺🇸 Small Cap Growth FundThe Variable Annuity Life Insurance Company94,936$3 M0.19%0.49%−5.9%May 31, 2026
🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC89,168$3 M0.18%0.05%−1.2%May 29, 2026
🇺🇸 Clearwater Select Equity FundClearwater Management Co Inc.67,706$2 M0.14%0.48%+10%Jun 30, 2026
🇺🇸 Federated Hermes MDT Small Cap Growth FundFederated Hermes MDT Series60,521$2 M0.12%0.28%newJul 31, 2026
🇺🇸 ARK Israel Innovative Technology ETFARK Investment Management LLC54,250$2 M0.11%1.5%−47%Jul 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC52,750$2 M0.11%0.05%+9.5%Jul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors52,288$2 M0.11%0.01%−16%Jun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC46,239$2 M0.09%0.04%+7.0%Jun 30, 2026
🇺🇸 Tema Oncology ETFTema ETFs LLC58,518$2 M0.12%0.93%−13%May 31, 2026
🇺🇸 Amplify BlueStar Israel Technology ETFAmplify ETF Trust43,319$2 M0.09%1.3%+44%Jun 30, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC37,512$1 M0.08%0.15%+201%Jul 31, 2026
🇺🇸 M Capital Appreciation FundNorthern Lights Fund Trust II36,861$1 M0.08%0.43%—Jun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC34,807$1 M0.07%<0.01%no changeJul 31, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC34,456$1 M0.07%0.08%+37%Jun 30, 2026
🇺🇸 iShares U.S. Small-Cap Equity Factor ETFBlackRock Fund Advisors30,659$1 M0.06%0.03%newJul 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation30,200$1 M0.06%0.05%+20%Jun 30, 2026
🇺🇸 State Street SPDR S&P International Small Cap ETFSSGA Funds Management, Inc.25,821$1 M0.05%0.11%+49%Jun 30, 2026
🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc.33,104$1 M0.07%0.05%−59%May 31, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC25,250$1 M0.05%0.05%+40%Jun 30, 2026
🇺🇸 Schwab Small-Cap Equity FundCharles Schwab Investment Management, Inc.23,370$1 M0.05%0.14%newJul 31, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.31,194$1 M0.06%0.05%+13%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC30,686$1 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.21,528$1 M0.04%0.05%+12%Jun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC20,398$1 M0.04%0.05%+17%Jul 31, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC19,515$1 M0.04%0.11%no changeJun 30, 2026
🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC18,561$1 M0.04%0.02%+2.9%Jul 31, 2026
🇺🇸 M Capital Appreciation FundM Financial Investment Advisers, Inc.37,221$1 M0.08%0.25%—Mar 31, 2026
🇺🇸 LVIP Franklin Templeton Multi-Factor SMID Cap Equity FundLincoln Financial Investments Corporation17,633$1 M0.04%0.06%+5.8%Jun 30, 2026
🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P.21,882$1 M0.04%0.06%+1.3%May 31, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors15,036$1 M0.03%<0.01%+57%Jun 30, 2026
🇺🇸 PACE Small/Medium Co Growth Equity InvestmentsUBS Asset Management (Americas) LLC14,146$1 M0.03%0.21%+163%Jul 31, 2026
🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC14,273$1 M0.03%0.14%+523%Jun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.14,200$1 M0.03%0.02%+3.6%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC14,183$1 M0.03%0.05%+23%Jun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC14,096$1 M0.03%0.05%+0.6%Jun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC13,730$1 M0.03%0.02%−1.4%Jun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.12,566$0 M0.03%<0.01%+189%Jun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC12,201$0 M0.02%0.05%+15%Jun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company15,749$0 M0.03%0.03%+7.6%May 31, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.11,210$0 M0.02%0.10%−2.8%Jun 30, 2026
🇺🇸 Column Small Cap FundTrust for Professional Managers14,607$0 M0.03%0.08%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index ETFFidelity Management & Research Company LLC14,314$0 M0.03%<0.01%+1.6%May 31, 2026
🇺🇸 Tax-Managed U.S. Mid & Small Cap FundRussell Investment Management, LLC9,452$0 M0.02%0.02%no changeJul 31, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors9,634$0 M0.02%0.01%−43%Jun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC9,556$0 M0.02%0.16%+32%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS9,417$0 M0.02%0.05%+19%Jun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC8,547$0 M0.02%0.05%+17%Jun 30, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC8,068$0 M0.02%0.01%−7.5%Jun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC6,726$0 M0.01%0.02%+23%Jul 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.6,694$0 M0.01%0.05%+19%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.6,425$0 M0.01%0.05%+36%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC6,291$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC5,736$0 M0.01%0.05%+16%Jun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC5,347$0 M0.01%0.04%+18%Jun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC5,152$0 M0.01%0.05%+19%Jun 30, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC5,128$0 M0.01%0.08%+76%Jun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC4,797$0 M<0.01%0.05%+18%Jul 31, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION5,900$0 M0.01%0.01%no changeMay 31, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.5,556$0 M0.01%0.01%+17%May 31, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS3,759$0 M<0.01%0.05%+15%Jul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management3,867$0 M<0.01%0.05%+25%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC3,455$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC3,386$0 M<0.01%0.05%+18%Jun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC3,206$0 M<0.01%<0.01%+55%Jul 31, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC3,222$0 M<0.01%0.08%+31%Jun 30, 2026
🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC6,541$0 M0.01%0.07%—Mar 31, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC3,016$0 M<0.01%<0.01%+87%Jul 31, 2026
🇺🇸 Avantis Total Equity Markets ETFAmerican Century ETF Trust3,775$0 M<0.01%0.01%no changeMay 31, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC2,859$0 M<0.01%0.05%+15%Jun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.3,496$0 M<0.01%<0.01%+20%May 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC1,845$0 M<0.01%<0.01%−34%Jun 30, 2026
🇺🇸 iShares MSCI World Small-Cap ETFBlackRock Fund Advisors2,395$0 M<0.01%0.01%newMay 31, 2026
🇺🇸 Strategic Allocation: Aggressive FundAmerican Century Strategic Asset Allocations Inc1,558$0 M<0.01%<0.01%−5.4%Jul 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC1,488$0 M<0.01%0.02%+26%Jun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC1,894$0 M<0.01%0.03%+19%May 31, 2026
🇺🇸 AVIP BlackRock Advantage Small Cap Growth PortfolioCONSTELLATION INVESTMENTS INC1,433$0 M<0.01%0.04%−64%Jun 30, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC1,500$0 M<0.01%0.01%−34%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC1,481$0 M<0.01%0.02%−35%May 31, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.1,076$0 M<0.01%<0.01%+26%Jun 30, 2026
🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC1,318$0 M<0.01%<0.01%−5.0%May 31, 2026
🇺🇸 Strategic Allocation: Moderate FundAmerican Century Strategic Asset Allocations Inc967$0 M<0.01%<0.01%−28%Jul 31, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC936$0 M<0.01%<0.01%−18%Jun 30, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS784$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC762$0 M<0.01%<0.01%+2.4%Jun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC907$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 TIAA Separate Account VA-1 - Stock Index AccountTeachers Advisors, LLC525$0 M<0.01%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at UroGen Pharma Ltd.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$4.5 M
14 sales, 3 insiders
Net, 12 months
-$4.5 M
open market only
Insiders on file
17
since
-$2.9 M$0Jan 2024: bought $0 (0 trades), sold $138 K (6 trades)Jan 24Mar 2024: bought $0 (0 trades), sold $169 K (1 trades)Jun 2024: bought $0 (0 trades), sold $67 K (1 trades)Sep 2024: bought $0 (0 trades), sold $31 K (2 trades)SepJan 2025: bought $0 (0 trades), sold $133 K (6 trades)Jun 2025: bought $0 (0 trades), sold $38 K (1 trades)Jul 2025: bought $0 (0 trades), sold $243 K (2 trades)JulAug 2025: bought $0 (0 trades), sold $177 K (1 trades)Sep 2025: bought $0 (0 trades), sold $46 K (2 trades)Oct 2025: bought $0 (0 trades), sold $37 K (1 trades)OctNov 2025: bought $0 (0 trades), sold $250 K (1 trades)Feb 2026: bought $0 (0 trades), sold $292 K (6 trades)May 2026: bought $0 (0 trades), sold $300 K (1 trades)MayJun 2026: bought $0 (0 trades), sold $493 K (2 trades)Jul 2026: bought $0 (0 trades), sold $400 K (1 trades)Aug 2026: bought $0 (0 trades), sold $2.9 M (1 trades)AugSep 2026: bought $0 (0 trades), sold $102 K (2 trades)Oct 2026: bought $0 (0 trades), sold $81 K (1 trades)
Bought (open market)Sold (open market)Hover a month for the totals
UroGen Pharma Ltd.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Chris DegnanChief Financial OfficerOption exercise+4,483——6,763Form 4
filed Chris DegnanChief Financial OfficerSell-2,202$36.69$81 K4,561Form 4
filed Jason Drew SmithGeneral CounselSell-1,519$42.54$65 K53,141Form 4
filed Mark SchoenbergChief Medical OfficerSell-871$42.92$37 K59,882Form 4
filed Jason Drew SmithGeneral CounselOption exercise+3,334——54,660Form 4
filed Mark SchoenbergChief Medical OfficerOption exercise+1,667——60,753Form 4
filed James A. Robinson Jr.DirectorOption exercise+2,000——8,000Form 4
filed Mark SchoenbergChief Medical OfficerSell-60,677$47.05$2.9 M59,086Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: UroGen Pharma Ltd.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
5.1 M
10.6% of shares · 5.09 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 3.2-for-1 split

Trading halts

  • 2025-06-12 15:56 UTC, code T3, resumed 18:00 UTC
  • 2025-05-21 10:55 UTC, code T3, resumed 16:55 UTC

Fails to deliver

  • : 146,112 shares at $36.58
  • : 185 shares at $38.26
  • : 39,984 shares at $38.28
  • : 200 shares at $40.70
  • : 9,187 shares at $41.23

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

UroGen Pharma Ltd. scorecard#

Passes 6 of the 17 checks that could be worked out: strongest in growth (4 of 5), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 15, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • ✗Price to sales below its peers' median16.3×Price to sales 16.3× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-9.1%Free cash flow is -9.1% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth4 of 5
    • ✓Revenue grew in the newest year21.4%Revenue up 21.4% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years19.5%19.5% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median19.5%19.5% a year against Biotechnology's median of 12.9% (181 companies).
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • ✗Net income higher than five years earlier-$153 M-$153 M in fiscal 2025 against -$128 M in 2020.
    • ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
  • Profitability1 of 4
    • ✗Profitable in the newest year-$153 MNet income -$153 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-113.7%-113.7% against Biotechnology's median of -60.5% (243 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-113.7%-113.7% in fiscal 2025 against -122.8% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities4.0×Current ratio 4.01 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-3.86Z-score -3.86 (distress zone) for fiscal 2025.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from UroGen Pharma Ltd.'s statements, beside the median of Biotechnology.

UroGen Pharma Ltd.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-113.7%-60.5%
Net margin-139.8%-68.9%
Revenue growth, 3 years a year19.5%12.9%
Revenue growth21.5%15.8%
Free cash flow margin-148.2%-61.5%

1of 9on the Piotroski tests of financial strength

  • Net loss of $153 million, the 11th loss-making year in a row.
  • Free cash flow was negative: -$163 million.
  • Shareholders' equity is negative: -$105 million.
  • Receivables grew 63% while revenue grew 21%: customers are paying later, or sales were booked ahead of cash.

UroGen Pharma Ltd.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

UroGen Pharma Ltd.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue11090836448120.01.18.218
Cost of revenue128.99.47.75.21.0—1.80.60.0
Gross profit9782735743110.0−0.77.618
Research and development675746534847493719—
Selling, general and administrative1551219383889060———
General and administrative——————60408.86.4
Operating expenses——————1097728—
Operating income−125−97−66−79−92−127−109−77−200.8
Interest and finance income6.08.92.60.90.42.04.6———
Other non-operating income (expense)−0.7−0.20.80.1−0.2—−0.3−0.10.0—
Income before tax−153−124−98−108−109−125−105−76−20−1.9
Income tax0.12.83.91.81.43.4—0.10.0—
Net income attributable to shareholders−153−127−102−110−111−128−105−76−20−1.9
Earnings per share, basic-3.19-2.96-3.55-4.81-4.96-5.90-5.12-4.80-2.14-1.91
Earnings per share, diluted————-4.96-5.90-5.12-4.80-2.14-1.91
Shares, weighted average (basic)4843292322—————
Shares, weighted average (diluted)————222221169.72.3
Balance sheet
Cash and cash equivalents11117295554453501013721
Short-term investments49111r56r45454997—36—
Receivables33201513127.0———0.1
Inventory169.25.74.34.82.0——0.30.1
Other current assets158.810117.53.41.00.71.00.4
Current assets1862761691291141161491027422
Property, plant and equipment0.60.70.71.32.02.01.00.90.80.7
Right-of-use (leased) assets3.10.80r2.51.22.23.7———
Total assets2002861781361201222021047623
Accounts payable12116.55.55.83.34.74.32.8r1.9
Current liabilities46463124222119137.03.1
Long-term debt12212299980—————
Lease liabilities (non-current)2.6r0.10r1.60.41.52.6———
Total liabilities3062952442251112622137.06.7
Retained earnings−960−806−679−577−467−357−228−123−47−27
Shareholders' equity−105−8.8−65−898.496180906916
Total liabilities and equity2002861781361201222021047623
Shares outstanding4842322322222116142.3
Cash-flow statement
Depreciation and amortization0.30.30.80.90.80.4r0.30.40.20.2
Share-based compensation12139.311232830316.32.0
Cash from operating activities−162−97−76−88−85−106−71−37−9.6r4.2
Capital expenditure−0.3−0.3−0.2−0.3−0.8−1.2−0.3−0.6−0.3−0.7
Cash from investing activities62−21−1.01.14.193−14635−36r−0.7r
Debt issued0240960—————
Shares issued401516700161626461—
Cash from financing activities401951179772171656662−0.0
Change in cash−61774011−8.53.9−516416r3.5r
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What UroGen Pharma Ltd. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Jelmyto$94 M86%
  • Zusduri$16 M14%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where UroGen Pharma Ltd. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.

Present: offices, subsidiaries, branches or revenue (2 countries)Nothing on fileDots mark countries too small to see. Hover, tap or tab to a country for its figures.
UroGen Pharma Ltd.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters—
🇮🇱 Israel1 office—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at UroGen Pharma Ltd.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$4.3 M
Elizabeth A. Barrett
Other top executives, average
$1.2 M
the CEO earned 3.6× this
$100 invested is now
$264
UroGen Pharma Ltd.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Elizabeth A. Barrett$4.3 M$11.8 M$1.2 M$264
2024Elizabeth A. Barrett$4.1 M$1.9 M$1.2 M$120
2023Elizabeth A. Barrett$4.6 M$6.3 M$1.4 M$169

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at UroGen Pharma Ltd.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 6 · Material agreement 3 · New debt 2 · Unregistered share sale 1 · Shareholder rights changed 1 · Shareholder vote 3 · Results announced 10

UroGen Pharma Ltd.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Directors and officersShareholder rights changedShareholder vote8-K
Results announced8-K
Material agreementNew debt8-K
Results announced8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Directors and officers8-K
New debt8-K
Directors and officers8-K
Results announced8-K
Directors and officersShareholder vote8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 4, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of UroGen Pharma Ltd.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2023$120 MPrivate placement after listing$50 to $250 million8equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by UroGen Pharma Ltd.#

$120 K spent on lobbying the US Congress and federal agencies in 2025.

Lobbying, 2025
$120 K
#1,188 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
$90 K

Lobbying firms hired in 2025

BGR Government Affairs $120 K

UroGen Pharma Ltd.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$90 K—3
2025$120 K—4
2024$90 K—4
2023$120 K—4
2022$220 K—5
2021$160 K—4
2020$160 K—4

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “UroGen Pharma, Inc.” and “UroGen Pharma Ltd.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at UroGen Pharma Ltd.#

1 labor condition applications certified in fiscal 2022 for 1 positions, at a median wage of $115 K a year.

Certified, FY2022
1
#1,972 among companies on value.today
Worker positions
1
Median wage offered
$115 K
a year, full-time
Applications filed
2
UroGen Pharma Ltd.: most frequent H-1B job titles in fiscal 2022
Job titlePositionsMedian wage offered
Senior Manager, Data ManagementClinical Data Managers1$115 K

Where: Princeton, NJ 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as UroGen Pharma, Inc.

FDA drug approvals: UroGen Pharma Ltd.#

2 approved applications held; 1 approvals and 0 new uses in 2025.

Approvals held
2
New molecular entities
0
New uses approved
0
efficacy supplements
Generics
0
2 new drugs, 0 biologics
UroGen Pharma Ltd.: latest FDA approvals
ApprovedDrugKind
2025-06-12ZusduriMitomycin · NDA215793New drug (NDA)
2020-04-15JelmytoMitomycin · NDA211728New drug (NDA)

Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (UROGEN PHARMA), so they follow acquisitions

Discuss UroGen Pharma Ltd.#

3 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 4 November 2026automatic update · Nov 4, 2026

    UroGen Pharma Ltd. announced results on 4 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: revenue of $89 million (up 224% from a year earlier) and a net loss of $1 million.

  • Insider trading in October 2026automatic update · Oct 31, 2026

    Directors and officers of UroGen Pharma Ltd. reported open-market trades for October 2026 (SEC Forms 4 and 5): 1 insider sold shares worth about $80,791 in 1 trade. Awards, option exercises and shares withheld for tax are not counted.

  • Mutual funds: 107 funds hold $211 millionautomatic update · Jul 31, 2026

    107 mutual funds in 1 country hold shares of UroGen Pharma Ltd. worth $211 million, about 12.0% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 68 funds added shares and 24 sold; on balance they bought $26 million. Share splits are not counted as trading.

How UroGen Pharma Ltd. compares in Biotechnology

  • Market cap$1.8 B · higher than 77% of 726
  • Revenue$110 M · higher than 70% of 647
  • Net margin-139.8% · higher than 37% of 408
  • Revenue growth21.4% · higher than 63% of 438
  • Price / sales16.3× · lower than 35% of 339
  • FCF yield-9.1% · higher than 59% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
UroGen Pharma Ltd.🇺🇸$1.8 B—-139.8%+21.4%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 15, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at UroGen Pharma Ltd.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show UroGen Pharma Ltd.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about UroGen Pharma Ltd.? Suggest a correction